OpenLB
Open Library of Bioscience
Advanced Search
Iranian journal of basic medical sciences
Mar, 2013;16 (3): 179-95.

Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL).

Sanaz Ahmadi Ghezeldasht, Abbas Shirdel, Mohammad Ali Assarehzadegan, Tahereh Hassannia, Hosian Rahimi, Rahele Miri, S A Rahim Rezaee
Author Information
  1. Sanaz Ahmadi Ghezeldasht: Research Centre for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Centre for Education, Culture & Research (ACECR), Mashhad Branch, Mashhad, Iran.
  2. Abbas Shirdel: Inflammation and Inflammatory diseases research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran.
  3. Mohammad Ali Assarehzadegan: Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  4. Tahereh Hassannia: Internal Medicine Dept, Medical School, Arak University of Medical Sciences, Arak- Iran.
  5. Hosian Rahimi: Inflammation and Inflammatory diseases research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran.
  6. Rahele Miri: Research Centre for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Centre for Education, Culture & Research (ACECR), Mashhad Branch, Mashhad, Iran.
  7. S A Rahim Rezaee: Immunology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
PMID: 24470860

Abstract

The study of tumor viruses paves the way for understanding the mechanisms of virus pathogenesis, including those involved in establishing infection and dissemination in the host tumor affecting immune-compromised patients. The processes ranging from viral infection to progressing malignancy are slow and usually insufficient for establishment of transformed cells that develop cancer in only a minority of infected subjects. Therefore, viral infection is usually not the only cause of cancer, and further environmental and host factors, may be implicated. HTLV-I, in particular, is considered as an oncovirus cause of lymphoproliferative disease such as adult T cell leukemia/lymphoma (ATL) and disturbs the immune responses which results in HTLV-I associated meylopathy/tropical spastic parapresis (HAM/TSP). HTLV-I infection causes ATL in a small proportion of infected subjects (2-5%) following a prolonged incubation period (15-30 years) despite a strong adaptive immune response against the virus. Overall, these conditions offer a prospect to study the molecular basis of tumorgenicity in mammalian cells. In this review, the oncogencity of HTLV-I is being considered as an oncovirus in context of ATL.

Keywords

Adult T Cell Leukemia/Lymphoma HTLV-I Oncogenecity Oncoviruses

References

  1. Hum Immunol. 2003 Apr;64(4):453-7 [PMID: 12651071]
  2. J Biol Chem. 1998 Aug 14;273(33):21132-6 [PMID: 9694868]
  3. Mol Cell Biol. 1994 Jan;14(1):456-62 [PMID: 8264613]
  4. Cell. 1987 Jan 30;48(2):343-50 [PMID: 3026643]
  5. Blood. 2005 Dec 15;106(13):4294-302 [PMID: 16118323]
  6. Blood. 1992 Dec 15;80(12):3205-16 [PMID: 1361372]
  7. Blood. 1996 Sep 1;88(5):1551-60 [PMID: 8781409]
  8. J Immunol. 2001 Feb 1;166(3):1723-9 [PMID: 11160217]
  9. Neoplasia. 2004 May-Jun;6(3):266-78 [PMID: 15153339]
  10. Mol Cell Biol. 1994 Oct;14(10):6443-51 [PMID: 7935369]
  11. Hum Cell. 1993 Dec;6(4):266-72 [PMID: 8148307]
  12. J Immunol. 2005 Apr 1;174(7):4262-70 [PMID: 15778389]
  13. Mol Cell Biol. 1990 Jan;10(1):413-7 [PMID: 2403646]
  14. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S100-6 [PMID: 8797711]
  15. Oncogene. 1999 Apr 15;18(15):2441-50 [PMID: 10229195]
  16. Microbiol Mol Biol Rev. 1999 Jun;63(2):308-33 [PMID: 10357853]
  17. Leukemia. 2002 Jun;16(6):1069-85 [PMID: 12040438]
  18. Retrovirology. 2004 Apr 13;1:6 [PMID: 15169570]
  19. J Virol. 1999 Dec;73(12):9917-27 [PMID: 10559304]
  20. J Neuroimmunol. 1993 Feb;42(2):147-54 [PMID: 8429100]
  21. J Virol. 1986 Nov;60(2):394-9 [PMID: 3021974]
  22. Mol Cell Biol. 1998 Feb;18(2):721-31 [PMID: 9447968]
  23. Blood. 2009 Jun 25;113(26):6528-32 [PMID: 19411628]
  24. Neuroradiology. 2002 Jul;44(7):559-67 [PMID: 12136356]
  25. Methods. 1998 Sep;16(1):83-94 [PMID: 9774518]
  26. Mol Cell Biol. 1998 Jul;18(7):3744-51 [PMID: 9632757]
  27. Leuk Res Treatment. 2012;2012:259045 [PMID: 23198155]
  28. EMBO Rep. 2001 Jul;2(7):609-14 [PMID: 11454737]
  29. AIDS Res Hum Retroviruses. 2007 Sep;23(9):1146-9 [PMID: 17919111]
  30. J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [PMID: 12145525]
  31. Retrovirology. 2005 May 23;2:34 [PMID: 15910683]
  32. Science. 2003 Mar 14;299(5613):1713-6 [PMID: 12589003]
  33. Proc Natl Acad Sci U S A. 1990 Feb;87(3):1071-5 [PMID: 2300570]
  34. Virol J. 2012 Jan 14;9:18 [PMID: 22244529]
  35. J Virol. 1995 Sep;69(9):5806-11 [PMID: 7637025]
  36. Am J Hematol. 1997 Apr;54(4):306-12 [PMID: 9092686]
  37. Best Pract Res Clin Gastroenterol. 2008;22(6):1031-48 [PMID: 19187865]
  38. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [PMID: 2787512]
  39. Oncogene. 2000 Mar 9;19(11):1448-56 [PMID: 10723136]
  40. Retrovirology. 2004 Nov 23;1:39 [PMID: 15560845]
  41. Jpn J Cancer Res. 1993 Jan;84(1):1-3 [PMID: 8449820]
  42. Neurology. 1995 Jan;45(1):30-3 [PMID: 7824129]
  43. Rinsho Ketsueki. 2003 Nov;44(11):1095-100 [PMID: 14689874]
  44. Mol Cell. 2002 Oct;10(4):693-5 [PMID: 12419209]
  45. Annu Rev Immunol. 2001;19:475-96 [PMID: 11244044]
  46. Oncogene. 2002 Apr 11;21(16):2466-75 [PMID: 11971181]
  47. Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):691-700 [PMID: 10365395]
  48. Semin Cancer Biol. 2004 Dec;14(6):453-71 [PMID: 15489139]
  49. J Virol. 1999 Aug;73(8):6460-7 [PMID: 10400740]
  50. Oncogene. 2000 Feb 10;19(6):827-30 [PMID: 10698501]
  51. Oncogene. 2005 Jan 20;24(4):525-40 [PMID: 15580311]
  52. Oncogene. 2001 Jul 27;20(33):4484-96 [PMID: 11494144]
  53. J Neuroimmunol. 2004 Nov;156(1-2):188-94 [PMID: 15465610]
  54. AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [PMID: 11080812]
  55. Int J Hematol. 2009 Jan;89(1):128-129 [PMID: 19104908]
  56. Proc Natl Acad Sci U S A. 1989 May;86(9):3351-5 [PMID: 2541443]
  57. J Biol Chem. 1998 Sep 4;273(36):23598-604 [PMID: 9722600]
  58. Jpn J Radiol. 2009 Jan;27(1):4-19 [PMID: 19373526]
  59. Intern Med. 1996 Sep;35(9):742-5 [PMID: 8915704]
  60. Virology. 2006 Oct 25;354(2):225-39 [PMID: 16890266]
  61. Iran J Allergy Asthma Immunol. 2006 Dec;5(4):153-66 [PMID: 17237568]
  62. J Biol Chem. 2001 Aug 24;276(34):31851-7 [PMID: 11435441]
  63. Lab Invest. 1993 Nov;69(5):629-34 [PMID: 8246453]
  64. J Virol. 1993 Mar;67(3):1211-7 [PMID: 8437212]
  65. FEBS Lett. 1997 Apr 14;406(3):263-6 [PMID: 9136898]
  66. J Virol. 1993 Dec;67(12):7701-4 [PMID: 8230493]
  67. Clin Lab Haematol. 2003 Apr;25(2):111-7 [PMID: 12641615]
  68. J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):92-100 [PMID: 10534152]
  69. Int J Cancer. 1984 Oct 15;34(4):501-6 [PMID: 6092282]
  70. Virology. 1997 Oct 13;237(1):123-8 [PMID: 9344914]
  71. Nat Genet. 2001 Apr;27(4):427-30 [PMID: 11279526]
  72. Virology. 1995 Feb 1;206(2):1066-74 [PMID: 7856081]
  73. Leuk Lymphoma. 2007 Feb;48(2):330-6 [PMID: 17325893]
  74. An Med Interna. 1995 Jun;12(6):299-306 [PMID: 7548650]
  75. J Biol Chem. 1998 Jun 26;273(26):15891-4 [PMID: 9632633]
  76. Blood. 1999 Jul 1;94(1):372-3 [PMID: 10428547]
  77. Cell. 1998 Jun 26;93(7):1231-40 [PMID: 9657155]
  78. Leuk Lymphoma. 2009 Apr;50(4):645-7 [PMID: 19373664]
  79. Science. 1988 Jul 1;241(4861):89-92 [PMID: 2838905]
  80. J Virol. 2007 Nov;81(21):11900-7 [PMID: 17715223]
  81. J Virol. 1991 Dec;65(12):6892-9 [PMID: 1719236]
  82. Int J Cancer. 2004 Apr 20;109(4):559-67 [PMID: 14991578]
  83. Zentralbl Bakteriol. 1996 Mar;283(3):340-6 [PMID: 9138620]
  84. Curr Opin Pulm Med. 1998 Mar;4(2):98-102 [PMID: 9612672]
  85. J Virol. 2001 Jan;75(1):396-407 [PMID: 11119608]
  86. J Immunol. 1989 Apr 1;142(7):2279-89 [PMID: 2466894]
  87. Science. 2001 Aug 24;293(5534):1495-9 [PMID: 11520989]
  88. Prog Cell Cycle Res. 2000;4:157-62 [PMID: 10740823]
  89. J Gen Virol. 2006 Jul;87(Pt 7):1781-1804 [PMID: 16760382]
  90. Hokenfu Zasshi. 1984 Oct;40(10):876-96 [PMID: 6568344]
  91. Transfus Apher Sci. 2012 Oct;47(2):151-4 [PMID: 22858444]
  92. J Immunol. 1989 Jun 15;142(12):4493-9 [PMID: 2786034]
  93. Science. 1988 Sep 23;241(4873):1652-5 [PMID: 2843985]
  94. J Neuroimmunol. 2012 Sep 15;250(1-2):87-93 [PMID: 22727800]
  95. Blood. 2008 Jul 15;112(2):383-93 [PMID: 18467597]
  96. Oncogene. 2001 Apr 19;20(17):2055-67 [PMID: 11360190]
  97. J Immunol. 1995 Dec 1;155(11):5241-8 [PMID: 7594536]
  98. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7070-4 [PMID: 1386673]
  99. Cell. 2003 Nov 14;115(4):449-59 [PMID: 14622599]
  100. Int J Cancer. 1996 Jul 17;67(2):283-8 [PMID: 8760600]
  101. Nature. 1984 Jun 14-20;309(5969):640-2 [PMID: 6328324]
  102. J Virol. 1999 May;73(5):3709-17 [PMID: 10196263]
  103. Int J Cancer. 2004 Jul 1;110(4):621-5 [PMID: 15122598]
  104. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [PMID: 6326131]
  105. Immunogenetics. 1995;42(5):323-332 [PMID: 7590965]
  106. Blood. 1985 Jul;66(1):120-7 [PMID: 2988665]
  107. J Virol. 2001 Jan;75(2):1083-9 [PMID: 11134325]
  108. Lancet Infect Dis. 2007 Apr;7(4):266-81 [PMID: 17376384]
  109. J Virol. 1998 Nov;72(11):8852-60 [PMID: 9765430]
  110. J Virol. 1998 May;72(5):4458-62 [PMID: 9557741]
  111. Oncogene. 1992 Mar;7(3):433-7 [PMID: 1549359]
  112. J Virol. 1992 Mar;66(3):1737-45 [PMID: 1310774]
  113. Mol Cell Biol. 1998 Sep;18(9):5052-61 [PMID: 9710589]
  114. Jpn J Cancer Res. 1989 Oct;80(10):1016 [PMID: 2515174]
  115. J Med Virol. 1999 Dec;59(4):541-6 [PMID: 10534739]
  116. Nature. 1988 Jun 23;333(6175):776-8 [PMID: 2838755]
  117. Hum Gene Ther. 1998 Nov 20;9(17):2459-68 [PMID: 9853513]
  118. J Virol. 1994 May;68(5):3374-9 [PMID: 8151796]
  119. Virology. 1999 May 10;257(2):277-84 [PMID: 10329537]
  120. Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):207-17 [PMID: 11325603]
  121. J Virol. 1995 Mar;69(3):1834-41 [PMID: 7853524]
  122. J Virol. 1999 Feb;73(2):1271-7 [PMID: 9882331]
  123. Immunol Rev. 2003 Jun;193:58-69 [PMID: 12752671]
  124. Mol Cell Biol. 1998 Sep;18(9):5157-65 [PMID: 9710600]
  125. Virology. 1997 Apr 28;231(1):135-40 [PMID: 9143312]
  126. Clin Infect Dis. 1995 Oct;21(4):1014-6 [PMID: 8645790]
  127. Cancer Res. 1997 Nov 1;57(21):4862-7 [PMID: 9354450]
  128. Blood. 2005 Feb 1;105(3):1204-13 [PMID: 15471956]
  129. Microb Pathog. 1990 Apr;8(4):259-78 [PMID: 2200942]
  130. Proc Biol Sci. 2003 Mar 7;270(1514):523-30 [PMID: 12641908]
  131. Carcinogenesis. 2006 Apr;27(4):673-81 [PMID: 16308315]
  132. Mol Cell Biol. 1996 May;16(5):2083-90 [PMID: 8628274]
  133. J Biol Chem. 2004 Apr 30;279(18):18137-45 [PMID: 14963024]
  134. Int J Cancer. 1989 Feb 15;43(2):250-3 [PMID: 2917802]
  135. J Virol. 1991 Aug;65(8):4408-13 [PMID: 2072457]
  136. Oncogene. 2002 Apr 11;21(16):2493-503 [PMID: 11971184]
  137. Lancet. 1987 May 9;1(8541):1085-6 [PMID: 2883415]
  138. Oncogene. 1994 Mar;9(3):841-52 [PMID: 8108127]
  139. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8813-7 [PMID: 1528897]
  140. Blood. 2002 Jan 1;99(1):88-94 [PMID: 11756157]
  141. Oncogene. 1995 Mar 16;10(6):1199-207 [PMID: 7700645]
  142. J Immunol. 1997 Oct 15;159(8):3731-8 [PMID: 9378959]
  143. J Neurol Sci. 2004 Apr 15;219(1-2):157-61 [PMID: 15050452]
  144. J Biol Chem. 1999 Nov 26;274(48):34226-32 [PMID: 10567395]
  145. Blood. 1996 Oct 15;88(8):3065-73 [PMID: 8874205]
  146. Nature. 1998 Mar 19;392(6673):300-3 [PMID: 9521327]
  147. Curr Opin Immunol. 2003 Jun;15(3):315-20 [PMID: 12787757]
  148. EMBO J. 2001 Dec 3;20(23):6805-15 [PMID: 11726516]
  149. Front Biosci. 2002 Jan 01;7:d157-63 [PMID: 11779707]
  150. J Exp Med. 1990 Jul 1;172(1):121-9 [PMID: 2358774]
  151. Cancer Res. 1999 May 15;59(10):2307-12 [PMID: 10344734]
  152. J Virol. 1992 Jul;66(7):4570-5 [PMID: 1351105]
  153. Genes Dev. 2004 Sep 15;18(18):2195-224 [PMID: 15371334]
  154. J Virol. 1998 Nov;72(11):9396-9 [PMID: 9765496]
  155. Lancet. 1999 Jun 5;353(9168):1951-8 [PMID: 10371587]
  156. Genes Dev. 1989 Oct;3(10):1534-44 [PMID: 2482226]
  157. Genes Dev. 1993 Apr;7(4):705-18 [PMID: 8458581]
  158. Leukemia. 1992;6 Suppl 3:60S-63S [PMID: 1602828]
  159. Blood. 2005 Aug 1;106(3):1048-53 [PMID: 15840694]
  160. Science. 1993 Oct 15;262(5132):395-9 [PMID: 8211160]
  161. Mol Cell Biol. 1995 May;15(5):2809-18 [PMID: 7739562]
  162. Retrovirology. 2007 May 29;4:35 [PMID: 17535428]
  163. J Biol Chem. 1995 Dec 1;270(48):28503-6 [PMID: 7499359]
  164. Cell. 2001 Jul 13;106(1):83-93 [PMID: 11461704]
  165. Int Immunol. 2005 Jun;17(6):677-84 [PMID: 15908451]
  166. Trop Doct. 2011 Jul;41(3):129-31 [PMID: 21532001]
  167. J Biol Chem. 2000 Apr 14;275(15):11154-63 [PMID: 10753922]
  168. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7303-7 [PMID: 8346248]
  169. Oncogene. 1996 Apr 18;12(8):1645-52 [PMID: 8622884]
  170. J Infect Dis. 2004 Oct 1;190(7):1279-85 [PMID: 15346339]
  171. J Virol. 2002 Sep;76(18):9389-97 [PMID: 12186921]
  172. Virol J. 2012 Mar 23;9:71 [PMID: 22444832]
  173. J Neuroimmunol. 1993 Oct;48(1):59-69 [PMID: 7901234]
  174. Oncogene. 1999 Feb 18;18(7):1401-9 [PMID: 10050877]
  175. Cancer Res. 2004 Sep 1;64(17):6002-9 [PMID: 15342380]
  176. Biochem Biophys Res Commun. 2003 Sep 12;309(1):161-5 [PMID: 12943677]
  177. J Clin Invest. 1991 Sep;88(3):1038-42 [PMID: 1832173]
  178. AIDS Res Hum Retroviruses. 1995 Feb;11(2):307-13 [PMID: 7742044]
  179. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5642-6 [PMID: 8202541]
  180. Acad Radiol. 2012 Aug;19(8):952-7 [PMID: 22578413]
  181. Oncogene. 1993 Sep;8(9):2391-7 [PMID: 8361755]
  182. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1992 Jun;25(3):182-4 [PMID: 1395949]
  183. J Virol. 2004 Jun;78(12):6081-90 [PMID: 15163701]
  184. J Clin Virol. 2011 Nov;52(3):172-6 [PMID: 21840754]
  185. Ann Surg. 2004 Feb;239(2):238-43 [PMID: 14745332]
  186. Front Biosci. 2007 Jan 01;12:1496-507 [PMID: 17127397]
  187. J Clin Microbiol. 2003 Jun;41(6):2593-5 [PMID: 12791885]
  188. Gan To Kagaku Ryoho. 2005 Jun;32(6):867-71 [PMID: 15984534]
  189. J Clin Virol. 2012 Apr;53(4):302-7 [PMID: 22306271]
  190. FEBS Lett. 1995 Jan 16;358(1):34-8 [PMID: 7529718]
  191. J Virol. 1998 Aug;72(8):6348-55 [PMID: 9658074]
  192. Retina. 2005 Dec;25(8):1096-8 [PMID: 16340543]
  193. Intern Med. 1995 Nov;34(11):1130-3 [PMID: 8774979]
  194. Oncogene. 1999 Feb 11;18(6):1341-9 [PMID: 10022816]
  195. J Immunol. 1994 Jul 15;153(2):566-73 [PMID: 8021495]
  196. J Neurovirol. 1998 Dec;4(6):586-93 [PMID: 10065900]
  197. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2532-6 [PMID: 8460169]
  198. Mol Cell Biol. 2002 May;22(10):3327-38 [PMID: 11971966]
  199. Blood. 2010 Aug 26;116(8):1211-9 [PMID: 20448111]
  200. J Virol. 2000 Nov;74(21):9828-35 [PMID: 11024109]
  201. Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Sep;28(9):1234-8 [PMID: 2266630]
  202. Blood. 2006 Dec 15;108(13):3979-82 [PMID: 16917009]
  203. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [PMID: 7862633]
  204. Cell. 1987 Apr 10;49(1):47-56 [PMID: 3030566]
  205. Int J Cancer. 1992 Dec 2;52(6):877-80 [PMID: 1459728]
  206. J Infect Dis. 1999 Nov;180(5):1487-93 [PMID: 10515807]
  207. Nature. 1995 Aug 17;376(6541):602-5 [PMID: 7637811]
  208. Oncogene. 1992 Feb;7(2):257-62 [PMID: 1532242]
  209. Nature. 1995 Aug 17;376(6541):606-8 [PMID: 7637812]
  210. J Infect Dis. 2011 Apr 1;203(7):948-59 [PMID: 21402546]
  211. Front Biosci. 2005 Jan 01;10:431-45 [PMID: 15574380]
  212. J Virol. 2002 Apr;76(8):4022-33 [PMID: 11907241]
  213. J Virol. 1996 Jun;70(6):3599-605 [PMID: 8648694]
  214. Blood. 1988 Jan;71(1):263-6 [PMID: 2891388]
  215. Blood. 1998 Jun 15;91(12):4701-7 [PMID: 9616168]
  216. Nature. 1990 Nov 15;348(6298):245-8 [PMID: 2146511]
  217. J Clin Oncol. 1997 May;15(5):1778-85 [PMID: 9164185]
  218. Blood. 2005 Aug 1;106(3):988-95 [PMID: 15831709]
  219. Oncogene. 2005 Jul 7;24(29):4624-33 [PMID: 15735688]
  220. Virology. 1992 Mar;187(1):316-20 [PMID: 1736534]
  221. Blood. 2001 Feb 15;97(4):987-93 [PMID: 11159527]
  222. J Virol. 1998 Jan;72(1):633-40 [PMID: 9420268]
  223. Int J Hematol. 2003 Nov;78(4):280-96 [PMID: 14686485]
  224. EMBO J. 1995 Jun 15;14(12):2876-83 [PMID: 7796813]
  225. J Virol Methods. 2003 May;109(2):105-17 [PMID: 12711052]
Journal Article Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0HTLV-IinfectionTATLstudytumorvirushostviralusuallycellscancerinfectedsubjectscauseconsideredoncoviruscellimmuneVirusAdultLeukemia/Lymphomavirusespaveswayunderstandingmechanismspathogenesisincludinginvolvedestablishingdisseminationaffectingimmune-compromisedpatientsprocessesrangingprogressingmalignancyslowinsufficientestablishmenttransformeddevelopminorityThereforeenvironmentalfactorsmayimplicatedparticularlymphoproliferativediseaseadultleukemia/lymphomadisturbsresponsesresultsassociatedmeylopathy/tropicalspasticparapresisHAM/TSPcausessmallproportion2-5%followingprolongedincubationperiod15-30yearsdespitestrongadaptiveresponseOverallconditionsofferprospectmolecularbasistumorgenicitymammalianreviewoncogencitycontextHumanLymphotropicTypeOncogenesis:MolecularAspectsHostInteractionsPathogenesisCellOncogenecityOncoviruses

Similar Articles

Cited By